Close Menu

NEW YORK (360Dx) – Taiwanese pharma firm TaiRx has established a US-based corporation to commercialize a drug and companion diagnostic targeting the nodal protein, which has been linked to aggressiveness and drug resistance in a variety of cancers.

Formed in August, the Rockville, Maryland-based company, called TaiRx US, is a joint venture between TaiRx and BioHealth Innovation (BHI), a public-private partnership organization that promotes the development of biotech and health businesses in the Washington DC region.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.